Sandoz

News

NHS saving £300m with Humira biosimilar deal

The NHS is to save £300 million after striking deals with several manufacturers of low cost biosimilars of AbbVie’s Humira inflammatory diseases drug.

News

Sandoz axes filing of US Rituxan biosimilar

Sandoz has abandoned plans to get a cheaper biosimilar of Swiss rival Roche’s cancer drug Rituxan (rituximab) approved in the US.

News

Billions up for grabs as EU patent on AbbVie's Humira expire...

The patent for Humira, the world’s bestselling drug, expires in Europe today – opening the door for a host of cheaper biosimilars to hit the market.

News

Sandoz free to launch Humira biosimilar following AbbVie dea...

Novartis’ generics and biosimilars arm, Sandoz, has confirmed it is to launch its biosimilar of AbbVie’s Humira (adalimumab) in Europe this year after the two companies settled intellectual

Views & Analysis

Digital health round-up - government and Sandoz recognise tr...

Richard Staines presents his weekly round-up of the latest digital health headlines

News

Sandoz encourages digital health innovation in second compet...

Sandoz has announced a second competition inviting entrepreneurs and innovators in digital health to submit ideas that could complement or even disrupt established approaches to access to h

NHS saving £300m with Humira biosimilar deal

Sandoz axes filing of US Rituxan biosimilar

Billions up for grabs as EU patent on AbbVie's Humira expire...

Sandoz free to launch Humira biosimilar following AbbVie dea...

Digital health round-up - government and Sandoz recognise tr...

Sandoz encourages digital health innovation in second compet...

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

Sandoz

Editor's Picks